Burcon NutraScience Corp
No enriched coverage for $BRCNF in the last 7 days.
No SEC Form 4 filings for $BRCNF in the last 30 days.
See all $BRCNF insider activity →Burcon NutraScience (TSX: BU) upsized its convertible debenture financing from $8.1M to $21M due to strong investor interest. The company postponed its AGSM to September 24, 2026, to allow shareholders to review updated materials. Proceeds will fund growth, efficiency, and debt repayment. The TSX conditionally approved the offering, subject to shareholder approval.
Stonegate Capital Partners updated coverage on Burcon Nutrascience Corporation (BU) after its 1Q27 results. The company reported revenue of $1.28M, up 54% quarter over quarter and 273% year over year, with active buying customers rising to 40. Stonegate noted a $1.76M inventory write-down and said execution depends on customer traction, Galesburg capacity expansion, and planned up to $8.1M financing to support a 2H ramp.
Burcon NutraScience (TSX: BU, OTCQB: BRCNF) reported fiscal 2027 Q1 results for the three months ended June 30, 2026. Revenue rose to C$1.3 million, up 54% sequentially and 273% year over year. Net loss was C$3.8 million (C$0.30/share). Cash was C$0.9 million with negative working capital. The company also announced a C$1.4 million related-party loan and a private placement of convertible debentures up to C$8.1 million.
Recent BRCNF coverage spans corporate actions and financial news.
Burcon NutraScience (TSX: BU) upsized its convertible debenture financing from $8.1M to $21M due to strong investor interest. The company postponed its AGSM to September 24, 2026, to allow shareholders to review updated materials. Proceeds will fund growth, efficiency, and debt repayment. The TSX conditionally approved the offering, subject to shareholder approval.
Stonegate Capital Partners updated coverage on Burcon Nutrascience Corporation (BU) after its 1Q27 results. The company reported revenue of $1.28M, up 54% quarter over quarter and 273% year over year, with active buying customers rising to 40. Stonegate noted a $1.76M inventory write-down and said execution depends on customer traction, Galesburg capacity expansion, and planned up to $8.1M financing to support a 2H ramp.
Burcon NutraScience (TSX: BU, OTCQB: BRCNF) reported fiscal 2027 Q1 results for the three months ended June 30, 2026. Revenue rose to C$1.3 million, up 54% sequentially and 273% year over year. Net loss was C$3.8 million (C$0.30/share). Cash was C$0.9 million with negative working capital. The company also announced a C$1.4 million related-party loan and a private placement of convertible debentures up to C$8.1 million.
alphai scores every news story that mentions BRCNF with an AI model for sentiment and relevance, and aggregates insider trades from Burcon NutraScience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Burcon NutraScience (TSX: BU) upsized its convertible debenture financing from $8.1M to $21M due to strong investor interest. The company postponed its AGSM to September 24, 2026, to allow shareholders to review updated materials. Proceeds will fund growth, efficiency, and debt repayment. The TSX conditionally approved the offering, subject to shareholder approval.
2 min readStonegate Capital Partners updated coverage on Burcon Nutrascience Corporation (BU) after its 1Q27 results. The company reported revenue of $1.28M, up 54% quarter over quarter and 273% year over year, with active buying customers rising to 40. Stonegate noted a $1.76M inventory write-down and said execution depends on customer traction, Galesburg capacity expansion, and planned up to $8.1M financing to support a 2H ramp.
2 min readBurcon NutraScience (TSX: BU, OTCQB: BRCNF) reported fiscal 2027 Q1 results for the three months ended June 30, 2026. Revenue rose to C$1.3 million, up 54% sequentially and 273% year over year. Net loss was C$3.8 million (C$0.30/share). Cash was C$0.9 million with negative working capital. The company also announced a C$1.4 million related-party loan and a private placement of convertible debentures up to C$8.1 million.
6 min read
